2-羟基丙脒 | 91431-03-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-羟基丙脒
• 中文别名: 2-羟基丙脒盐酸盐
• 英文名称: lactamidine
• 英文别名: Lactamidin；α-Oxy-propionamidin；2-Hydroxy-propionamidin；Milchsaeureamidin；Propanol-(2)-amidin-(1)；α-Hydroxy-propionsaeureamidin；2-hydroxypropanimidamide
• CAS: 91431-03-7
• 化学式: C₃H₈N₂O
• mdl: MFCD05663166
• 分子量: 88.1093
• InChiKey: HLGDWKWUYZNZIF-UHFFFAOYSA-N

物化性质

• 沸点：
  176.9±42.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  70.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-羟基丙脒 、 sodium 3-ethoxy-3-oxoprop-1-en-1-olate 在 水 作用下， 生成 2-(1-羟基乙基)嘧啶-4(3H)-酮
  参考文献：
  名称：

  Sorbitol Dehydrogenase Inhibitors (SDIs):  A New Potent, Enantiomeric SDI, 4-[2-1R-Hydroxy-ethyl)-pyrimidin-4-yl]-piperazine-1-sulfonic Acid Dimethylamide

  摘要：

  We report here on our medicinal chemistry and pharmacology efforts to provide a potent sorbitol dehydrogenase inhibitor (SDI) as a tool to probe a recently disclosed hypothesis centered on the role of sorbitol dehydrogenase (SDH) in the second step of the polyol pathway, under conditions of high glucose flux. Starting from a weak literature lead, 2, and through newly developed structure-activity relationships, we have designed and executed an unambiguous synthesis of enantiomeric SDI, 6, which is at least 10x more potent than 2. Also, 6 potently inhibits SDH in streptozotocin-diabetic rat sciatic nerve. We have described an expedient synthesis of a key building template, 33, for future research in the SDI area that may facilitate the discovery of even more potent SDIs with longer duration of action in vivo.

  DOI：

  10.1021/jm0102001
• 作为产物：
  描述：

  ethyl 2-hydroxypropanimidate hydrochloride 在 氨 作用下， 以 乙醇 为溶剂， 反应 17.5h， 以75%的产率得到2-羟基丙脒
  参考文献：
  名称：

  [EN] 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS
  [FR] DÉRIVÉS DE L'ACIDE 2-(PIPÉRIDINE-1-YL)-4-HÉTÉROCYCLYL-THIAZOLE-5-CARBOXYLIQUE UTILISÉS POUR LUTTER CONTRE LES INFECTIONS BACTÉRIENNES

  摘要：

  化合物的结构式（I）及其药用盐已经描述。还描述了它们的制备方法、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。环A从式（a）、（b）或（b'）中选择。

  公开号：

  WO2010067123A1

文献信息

• Pinner, Chemische Berichte, 1890, vol. 23, p. 2953
  作者：Pinner

  DOI：——

  日期：——
• [EN] 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DE L'ACIDE 2-(PIPÉRIDINE-1-YL)-4-HÉTÉROCYCLYL-THIAZOLE-5-CARBOXYLIQUE UTILISÉS POUR LUTTER CONTRE LES INFECTIONS BACTÉRIENNES
  申请人：ASTRAZENECA AB

  公开号：WO2010067123A1

  公开（公告）日：2010-06-17

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. Ring A is selected from formula (a), (b) or (b'):

  化合物的结构式（I）及其药用盐已经描述。还描述了它们的制备方法、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。环A从式（a）、（b）或（b'）中选择。
• Sorbitol Dehydrogenase Inhibitors (SDIs):  A New Potent, Enantiomeric SDI, 4-[2-1<i>R</i>-Hydroxy-ethyl)-pyrimidin-4-yl]-piperazine-1-sulfonic Acid Dimethylamide
  作者：Banavara L. Mylari、Peter J. Oates、David A. Beebe、Nathaniel S. Brackett、James B. Coutcher、Michael S. Dina、William J. Zembrowski

  DOI：10.1021/jm0102001

  日期：2001.8.1

  We report here on our medicinal chemistry and pharmacology efforts to provide a potent sorbitol dehydrogenase inhibitor (SDI) as a tool to probe a recently disclosed hypothesis centered on the role of sorbitol dehydrogenase (SDH) in the second step of the polyol pathway, under conditions of high glucose flux. Starting from a weak literature lead, 2, and through newly developed structure-activity relationships, we have designed and executed an unambiguous synthesis of enantiomeric SDI, 6, which is at least 10x more potent than 2. Also, 6 potently inhibits SDH in streptozotocin-diabetic rat sciatic nerve. We have described an expedient synthesis of a key building template, 33, for future research in the SDI area that may facilitate the discovery of even more potent SDIs with longer duration of action in vivo.